150
Participants
Start Date
June 14, 2024
Primary Completion Date
September 30, 2026
Study Completion Date
October 31, 2026
Cadisegliatin 800 mg QD
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.
Cadisegliatin 800 mg BID
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.
Placebo
Placebo (insulin alone)
RECRUITING
Jacobi Medical Center, The Bronx
RECRUITING
University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia
RECRUITING
University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
Lucas Research, Inc, Morehead City
RECRUITING
Endocrine Research Solutions, Inc, Roswell
RECRUITING
East Coast Institute for Research, LLC, Canton
RECRUITING
Atlanta Diabetes Associates, Atlanta
RECRUITING
The Jones Center Clinical Research, LLC, Macon
RECRUITING
Centricity Research - Columbus, Columbus
RECRUITING
ALL Medical Research, LLC, Cooper City
RECRUITING
Metabolic Research Institute, Inc, West Palm Beach
RECRUITING
Iowa Diabetes and Endocrinology Research Center, West Des Moines
RECRUITING
Southern Endocrinology Associates PA, Mesquite
RECRUITING
Velocity Clinical Research - Dallas, Dallas
RECRUITING
Diabetes & Glandular Disease Clinic, P.A., San Antonio
RECRUITING
Consano Clinical Research, Shavano Park
RECRUITING
Texas Diabetes and Endocrinology, P.A, Austin
RECRUITING
Denver Endocrinology Diabetes and Thyroid Center, Englewood
WITHDRAWN
Advanced Research Institute - Ogden, Ogden
RECRUITING
Vector Clinical Trials, Sparks
RECRUITING
Advanced Metabolic Care & Research Institute, Inc. (AMCR), Escondido
RECRUITING
Scripps Whittier Diabetes Institute, La Jolla
RECRUITING
Velocity Clinical Research - Medford, Medford
Lead Sponsor
vTv Therapeutics
INDUSTRY